Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.

Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, Evens AM.

Oncotarget. 2019 Mar 12;10(21):2030-2040. doi: 10.18632/oncotarget.26771. eCollection 2019 Mar 12.

2.

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Paudel N, Schulze D, Gentzler RD, Evens AM, Helenowski I, Dillehay G, Frankfurt O, Mehta J, Donnelly ED, Gordon LI, Winter JN, Mittal BB.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):436-446. doi: 10.1016/j.ijrobp.2019.02.007. Epub 2019 Feb 11.

PMID:
30763660
3.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
4.

Important new developments in Hodgkin Lymphoma.

Evens AM.

Br J Haematol. 2019 Jan;184(1):6. doi: 10.1111/bjh.15736. No abstract available.

PMID:
30589096
5.

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.

Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS.

Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.

PMID:
30575016
6.

Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.

Sabhachandani P, Sarkar S, Mckenney S, Ravi D, Evens AM, Konry T.

J Control Release. 2019 Feb 10;295:21-30. doi: 10.1016/j.jconrel.2018.12.010. Epub 2018 Dec 12.

PMID:
30550941
7.

Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.

McDonald JT, Kritharis A, Beheshti A, Pilichowska M, Burgess K, Ricks-Santi L, McNiel E, London CA, Ravi D, Evens AM.

Oncotarget. 2018 Sep 7;9(70):33441. doi: 10.18632/oncotarget.26114. eCollection 2018 Sep 7.

8.

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.

Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ.

Leuk Lymphoma. 2019 Apr;60(4):940-946. doi: 10.1080/10428194.2018.1515944. Epub 2018 Oct 2.

PMID:
30277110
9.

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD.

Leuk Lymphoma. 2019 Apr;60(4):894-903. doi: 10.1080/10428194.2018.1515940. Epub 2018 Oct 2.

PMID:
30277102
10.

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA.

J Clin Oncol. 2018 Oct 20;36(30):3015-3022. doi: 10.1200/JCO.2018.79.0139. Epub 2018 Sep 4.

PMID:
30179569
11.

Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.

McDonald JT, Kritharis A, Beheshti A, Pilichowska M, Burgess K, Ricks-Santi L, McNiel E, London CB, Ravi D, Evens AM.

Oncotarget. 2018 Apr 27;9(32):22693-22702. doi: 10.18632/oncotarget.25209. eCollection 2018 Apr 27. Erratum in: Oncotarget. 2018 Sep 7;9(70):33441.

12.

Author Correction: Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 May 3;8(1):7221. doi: 10.1038/s41598-018-25251-9.

13.

Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.

Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM.

Br J Haematol. 2018 Jul;182(2):212-221. doi: 10.1111/bjh.15255. Epub 2018 Apr 29.

14.

Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?

David KA, Kritharis A, Evens AM.

Lancet Haematol. 2018 May;5(5):e186-e187. doi: 10.1016/S2352-3026(18)30049-8. Epub 2018 Apr 9. No abstract available.

PMID:
29650494
15.

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.

Kapadia B, Nanaji NM, Bhalla K, Bhandary B, Lapidus R, Beheshti A, Evens AM, Gartenhaus RB.

Nat Commun. 2018 Feb 26;9(1):829. doi: 10.1038/s41467-018-03028-y.

16.

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 Jan 15;8(1):744. doi: 10.1038/s41598-018-19182-8. Erratum in: Sci Rep. 2018 May 3;8(1):7221.

17.

Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma.

Sarkar S, Sabhachandani P, Ravi D, Potdar S, Purvey S, Beheshti A, Evens AM, Konry T.

Front Immunol. 2017 Dec 14;8:1736. doi: 10.3389/fimmu.2017.01736. eCollection 2017.

18.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

19.

Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review.

Fu J, Upshaw J, Cohen J, Rodday AM, Saunders T, Kelly M, Evens AM, Parsons SK.

Leuk Lymphoma. 2018 Aug;59(8):1976-1980. doi: 10.1080/10428194.2017.1406086. Epub 2017 Dec 7. No abstract available.

PMID:
29214876
20.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

21.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM.

Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13.

22.

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM.

Br J Haematol. 2018 Apr;181(2):264-267. doi: 10.1111/bjh.14544. Epub 2017 Apr 17. No abstract available.

23.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

24.

A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma.

Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, Evens AM.

PLoS One. 2017 Jan 20;12(1):e0170521. doi: 10.1371/journal.pone.0170521. eCollection 2017.

25.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL.

J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw249. Print 2017 Apr. Review.

26.

Gray Zone Lymphoma: Current Diagnosis and Treatment Options.

Pilichowska M, Kritharis A, Evens AM.

Hematol Oncol Clin North Am. 2016 Dec;30(6):1251-1260. doi: 10.1016/j.hoc.2016.07.006. Review.

PMID:
27888879
27.

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.

Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M.

Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.

28.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

29.

Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.

Rosenberg AS, Ruthazer R, Paulus JK, Kent DM, Evens AM, Klein AK.

Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):684-692.e3. doi: 10.1016/j.clml.2016.09.002. Epub 2016 Sep 17.

30.

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.

Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ.

Oncotarget. 2016 Sep 13;7(37):59976-59986. doi: 10.18632/oncotarget.11045.

31.

Health-related quality of life in Hodgkin lymphoma: a systematic review.

Linendoll N, Saunders T, Burns R, Nyce JD, Wendell KB, Evens AM, Parsons SK.

Health Qual Life Outcomes. 2016 Jul 29;14(1):114. doi: 10.1186/s12955-016-0515-6. Review.

32.

How I manage patients with grey zone lymphoma.

Kritharis A, Pilichowska M, Evens AM.

Br J Haematol. 2016 Aug;174(3):345-50. doi: 10.1111/bjh.14174. Epub 2016 Jun 15. Review.

PMID:
27301470
33.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-1551. doi: 10.1016/j.bbmt.2016.04.019. Epub 2016 Apr 27. Review.

34.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW.

J Clin Oncol. 2016 Jun 10;34(17):2020-7. doi: 10.1200/JCO.2015.63.1119. Epub 2016 Apr 11.

35.

The evolving role of response-adapted PET imaging in Hodgkin lymphoma.

Coyle M, Kostakoglu L, Evens AM.

Ther Adv Hematol. 2016 Apr;7(2):108-25. doi: 10.1177/2040620715625615. Review.

36.

Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.

Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM.

Cancer Res. 2016 Jun 1;76(11):3319-31. doi: 10.1158/0008-5472.CAN-15-2477. Epub 2016 Mar 17.

37.

Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Rosenberg AS, Klein AK, Ruthazer R, Evens AM.

Am J Hematol. 2016 Jun;91(6):560-5. doi: 10.1002/ajh.24346. Epub 2016 Apr 26.

38.

The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks.

Beheshti A, Neuberg D, McDonald JT, Vanderburg CR, Evens AM.

Cancer Inform. 2015 Dec 10;14:141-8. doi: 10.4137/CIN.S34144. eCollection 2015.

39.

Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting.

Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F.

J Clin Oncol. 2016 Feb 10;34(5):501-8. doi: 10.1200/JCO.2015.62.4445. Epub 2015 Nov 30.

40.

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM.

Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2.

41.

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.

Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL.

Clin Cancer Res. 2016 Mar 1;22(5):1059-66. doi: 10.1158/1078-0432.CCR-15-0624. Epub 2015 Oct 19.

42.

Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissue.

Wage J, Ma L, Peluso M, Lamont C, Evens AM, Hahnfeldt P, Hlatky L, Beheshti A.

J Radiat Res. 2015 Sep;56(5):792-803. doi: 10.1093/jrr/rrv043. Epub 2015 Aug 7.

43.

A Clinico-Pathologic Correlation. Burkitt's lymphoma).

English R, Ashrafi A, Evens AM, Oreadi D.

J Mass Dent Soc. 2015 Spring;64(1):34-6. No abstract available.

PMID:
26168531
44.

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.

Am J Hematol. 2015 Sep;90(9):778-83. doi: 10.1002/ajh.24082.

45.

Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA; American Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jun;21(6):971-83. doi: 10.1016/j.bbmt.2015.02.022. Epub 2015 Mar 12.

46.

Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.

Kritharis A, Coyle M, Sharma J, Evens AM.

Blood. 2015 Apr 16;125(16):2471-6. doi: 10.1182/blood-2014-11-567792. Epub 2015 Mar 3.

47.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):135-43. doi: 10.1182/asheducation-2014.1.135. Epub 2014 Nov 18. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2015;2015:652.

PMID:
25696846
48.

Current therapeutic strategies and new treatment paradigms for follicular lymphoma.

Kritharis A, Sharma J, Evens AM.

Cancer Treat Res. 2015;165:197-226. doi: 10.1007/978-3-319-13150-4_8. Review.

PMID:
25655611
49.

Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder.

Shah U, Kritharis A, Evens AM.

Ann Hematol. 2015 May;94(5):893-4. doi: 10.1007/s00277-014-2277-8. Epub 2014 Dec 18. No abstract available.

50.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Blood. 2014 Nov 27;124(23):3356-64. doi: 10.1182/blood-2014-05-577627. Review. Erratum in: Blood. 2015 Apr 9;125(15):2450.

Supplemental Content

Loading ...
Support Center